126 related articles for article (PubMed ID: 33839731)
1. Rest or 30-Min Walk as Exercise Intervention (RESTOREX) in Myasthenia Gravis: A Randomized Controlled Trial.
Misra UK; Kalita J; Singh VK; Kapoor A; Tripathi A; Mishra P
Eur Neurol; 2021; 84(3):168-174. PubMed ID: 33839731
[TBL] [Abstract][Full Text] [Related]
2. The effects of spinal stabilization exercises in patients with myasthenia gravis: a randomized crossover study.
Ceren AN; Salcı Y; Fil Balkan A; Çalık Kütükçü E; Armutlu K; Erdem Özdamar S
Disabil Rehabil; 2022 Dec; 44(26):8442-8449. PubMed ID: 34978954
[TBL] [Abstract][Full Text] [Related]
3. Eculizumab improves fatigue in refractory generalized myasthenia gravis.
Andersen H; Mantegazza R; Wang JJ; O'Brien F; Patra K; Howard JF;
Qual Life Res; 2019 Aug; 28(8):2247-2254. PubMed ID: 30905021
[TBL] [Abstract][Full Text] [Related]
4. Effect of Exercise on β-Endorphin and Its Receptors in Myasthenia Gravis Patients.
Tripathi GM; Misra UK; Kalita J; Singh VK; Tripathi A
Mol Neurobiol; 2023 Jun; 60(6):3010-3019. PubMed ID: 36781738
[TBL] [Abstract][Full Text] [Related]
5. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF;
J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
Pasnoor M; He J; Herbelin L; Burns TM; Nations S; Bril V; Wang AK; Elsheikh BH; Kissel JT; Saperstein D; Shaibani JA; Jackson C; Swenson A; Howard JF; Goyal N; David W; Wicklund M; Pulley M; Becker M; Mozaffar T; Benatar M; Pazcuzzi R; Simpson E; Rosenfeld J; Dimachkie MM; Statland JM; Barohn RJ;
Neurology; 2016 Jul; 87(1):57-64. PubMed ID: 27306628
[TBL] [Abstract][Full Text] [Related]
8. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis.
Di L; Shen F; Wen X; Lu Y; Zhu W; Wang M; Da Y
Front Immunol; 2022; 13():839075. PubMed ID: 35371086
[TBL] [Abstract][Full Text] [Related]
10. Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study.
Bonanno S; Pasanisi MB; Frangiamore R; Maggi L; Antozzi C; Andreetta F; Campanella A; Brenna G; Cottini L; Mantegazza R
SAGE Open Med; 2018; 6():2050312118819013. PubMed ID: 30574306
[TBL] [Abstract][Full Text] [Related]
11. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
Howard JF; Nowak RJ; Wolfe GI; Freimer ML; Vu TH; Hinton JL; Benatar M; Duda PW; MacDougall JE; Farzaneh-Far R; Kaminski HJ; ; Barohn R; Dimachkie M; Pasnoor M; Farmakidis C; Liu T; Colgan S; Benatar MG; Bertorini T; Pillai R; Henegar R; Bromberg M; Gibson S; Janecki T; Freimer M; Elsheikh B; Matisak P; Genge A; Guidon A; David W; Habib AA; Mathew V; Mozaffar T; Hinton JL; Hewitt W; Barnett D; Sullivan P; Ho D; Howard JF; Traub RE; Chopra M; Kaminski HJ; Aly R; Bayat E; Abu-Rub M; Khan S; Lange D; Holzberg S; Khatri B; Lindman E; Olapo T; Sershon LM; Lisak RP; Bernitsas E; Jia K; Malik R; Lewis-Collins TD; Nicolle M; Nowak RJ; Sharma A; Roy B; Nye J; Pulley M; Berger A; Shabbir Y; Sachdev A; Patterson K; Siddiqi Z; Sivak M; Bratton J; Small G; Kohli A; Fetter M; Vu T; Lam L; Harvey B; Wolfe GI; Silvestri N; Patrick K; Zakalik K; Duda PW; MacDougall J; Farzaneh-Far R; Pontius A; Hoarty M
JAMA Neurol; 2020 May; 77(5):582-592. PubMed ID: 32065623
[TBL] [Abstract][Full Text] [Related]
12. Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial.
Hui D; Xu A; Frisbee-Hume S; Chisholm G; Morgado M; Reddy S; Bruera E
J Pain Symptom Manage; 2014 Feb; 47(2):209-17. PubMed ID: 23830530
[TBL] [Abstract][Full Text] [Related]
13. Home-based exercise in autoimmune myasthenia gravis: A randomized controlled trial.
Birnbaum S; Porcher R; Portero P; Clair B; Demeret S; Eymard B; Gargiulo M; Louët E; Berrih-Aknin S; Le Panse R; Aegerter P; Hogrel JY; Sharshar T;
Neuromuscul Disord; 2021 Aug; 31(8):726-735. PubMed ID: 34304969
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
15. Translation, cross-cultural adaptation, and validation of the french version of the 15-item Myasthenia Gravis Quality Of life scale.
Birnbaum S; Ghout I; Demeret S; Bolgert F; Eymard B; Sharshar T; Portero P; Hogrel JY
Muscle Nerve; 2017 May; 55(5):639-645. PubMed ID: 27533497
[TBL] [Abstract][Full Text] [Related]
16. Physical training and exercise in myasthenia gravis.
Gilhus NE
Neuromuscul Disord; 2021 Mar; 31(3):169-173. PubMed ID: 33461846
[TBL] [Abstract][Full Text] [Related]
17. Acetylcholinesterase inhibitor treatment for myasthenia gravis.
Mehndiratta MM; Pandey S; Kuntzer T
Cochrane Database Syst Rev; 2011 Feb; (2):CD006986. PubMed ID: 21328290
[TBL] [Abstract][Full Text] [Related]
18. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis.
Burns TM; Conaway MR; Cutter GR; Sanders DB;
Muscle Nerve; 2008 Aug; 38(2):957-63. PubMed ID: 18642357
[TBL] [Abstract][Full Text] [Related]
19. Functional exercise capacity evaluated by timed walk tests in myasthenia gravis.
Salci Y; Karanfil E; Balkan AF; Kütükçü EÇ; Ceren AN; Ayvat F; Bekircan-Kurt CE; Armutlu K
Muscle Nerve; 2019 Feb; 59(2):208-212. PubMed ID: 30230561
[TBL] [Abstract][Full Text] [Related]
20. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
Katyal N; Narula N; Govindarajan R
J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
